Apple Unveils $1,999 Foldable iPhone Duo 
Zara Owner Inditex Sales Rise 9% in August 
OpenAI Targets Specialized Industries as Enterprise AI Demand Grows 
Optus Apologises After Network Outage Disrupts Emergency Calls 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
Qualcomm Stock Jumps on Amazon AI Chip Deal 
Can Europe shake its Russia links for good? 
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Hyundai Delays In-House ADAS, Turns to Nvidia 
SpaceX Nasdaq 100 Weight Set to More Than Double 
Boeing, SPEEA Reach Tentative Four-Year Labor Deal 
Nvidia Eyes $10 Billion Investment in Anthropic IPO 
OpenAI Agents Used Websites for Unauthorized Communications 
Meta’s AI Shopping Push Grows as Agentic Commerce Remains Below 1% 
Huawei, Chinese AI Chipmakers Raise Prices as HBM Shortage Bites 
Add as a preferred source on Google
Samsung Biologics has announced plans to acquire Swiss contract drug manufacturer PolyPeptide in an all-cash deal valued at approximately 1.46 billion Swiss francs ($1.81 billion), strengthening its position in the fast-growing peptide therapeutics market.
Under the proposed transaction, Samsung Biologics will offer 44.31 Swiss francs per share, representing a 6.1% premium to PolyPeptide’s closing price of 41.75 Swiss francs on Friday. The South Korean biotech company expects to launch the tender offer by the end of August, with the acquisition targeted for completion before the end of the year.
The acquisition is part of Samsung Biologics’ strategy to expand its contract development and manufacturing capabilities, particularly in peptide-based medicines. The company sees strong growth opportunities in therapies for obesity and diabetes, including GLP-1 drugs, a segment experiencing surging global demand.
PolyPeptide’s board of directors has unanimously recommended that shareholders accept the offer, signaling strong support for the transaction.
Samsung Biologics also said it intends to acquire all remaining shares after the tender offer through a squeeze-out process, allowing it to delist PolyPeptide from the SIX Swiss Exchange and operate the company as a wholly owned subsidiary.
The deal already has the backing of Draupnir Holding, PolyPeptide’s largest shareholder, which controls approximately 55.65% of the company. Draupnir confirmed it will tender all of its shares into Samsung Biologics’ offer.
Earlier this year, PolyPeptide disclosed that Draupnir was reviewing strategic options for its majority stake. Draupnir’s parent organization, the Cryosphere Foundation, has previously been linked to Swedish billionaire Frederik Paulsen.
If completed, the acquisition would significantly enhance Samsung Biologics’ manufacturing portfolio and strengthen its presence in the rapidly expanding global market for peptide-based pharmaceutical ingredients. The move also reflects growing competition among contract drug manufacturers seeking to capitalize on increasing demand for innovative biologic and metabolic disease treatments.
